Spectral Diagnostics (OTCMKTS:EDTXF) Releases Earnings Results, Meets Expectations

Spectral Diagnostics (OTCMKTS:EDTXF) announced its quarterly earnings results on Thursday. The company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01), reports. The business had revenue of $0.28 million for the quarter, compared to analysts’ expectations of $0.54 million.

Spectral Diagnostics Trading Down 3.8%

Shares of OTCMKTS EDTXF traded down $0.04 during mid-day trading on Friday, hitting $1.02. The company had a trading volume of 100 shares, compared to its average volume of 8,680. Spectral Diagnostics has a 1 year low of $0.47 and a 1 year high of $1.31. The company has a market capitalization of $298.41 million, a price-to-earnings ratio of -9.27 and a beta of 0.04. The stock’s 50-day moving average price is $0.97 and its 200-day moving average price is $1.00.

About Spectral Diagnostics

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.